Vimarsana
Biggest News Aggregation in the World

Page 3 - Rd Fund News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Rd Fund. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Rd Fund Today - Breaking & Trending Today

Why Is vTv Therapeutics Stock Trading Higher Today? - Vimarsana News

Why Is vTv Therapeutics Stock Trading Higher Today?

Wednesday, vTv Therapeutics Inc VTVT shares are soaring on a robust session volume of 2.7 million, compared to the average volume of 31.92 K as per the data…

Source: biztoc.com
S&P 500 Edges Lower; ADT Posts Upbeat Earnings - ADT (NYSE:ADT), Adial Pharmaceuticals (NASDAQ:ADIL) - Vimarsana News

S&P 500 Edges Lower; ADT Posts Upbeat Earnings - ADT (NYSE:ADT), Adial Pharmaceuticals (NASDAQ:ADIL)

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.27% to 38,867.91 while the NASDAQ fell 0.50% to 15,954.75. The S&P 500 also fell, dropping, 0.18% to 5,068.92.

Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP - Vimarsana News

Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate , enabling the achievement of exogenous insulin independence without...

This Biotech Startup Just Raised $105M to Extinguish Inflammation at the Source - Vimarsana News

This Biotech Startup Just Raised $105M to Extinguish Inflammation at the Source

Cour Pharmaceuticals’ nanoparticles reprogram the immune system to stop inflammation behind autoimmune disease. Three big pharma companies joined the startup’s Series A financing, which will fund clinical trials in type 1 diabetes and myasthenia gravis.

Cour Pharmaceuticals Closes Approximately $105M Series A Funding - Vimarsana News

Cour Pharmaceuticals Closes Approximately $105M Series A Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!